Potential role for vaccine in malaria elimination

malaria
Credit: CDC

Although the World Health Organization decided not to recommend the use of RTS,S/AS01, the most advanced malaria vaccine candidate that is in development, in infants within the Expanded Programme of Immunisations (EPI), termination of further development of RTS,S/AS01 would be a loss for malaria elimination efforts according to Roly Gosling of the UCSF Global Health Group's Malaria Elimination Initiative and Lorenz von Seidlein of the Mahidol-Oxford Tropical Medicine Research Unit, Thailand.

Last year a large Phase III trial of RTS,S/AS01 in both infants aged 6 to 12 weeks and young children 5 to 15 months old, showed that waned rapidly and the addition of a booster dose 20 months after the first dose increased protection only slightly. While these findings are disappointing the authors argue that the potential benefit of the high initial protection afforded by the vaccine should not be forgotten and, following further research, the vaccine could potentially be used in intensive strategies in low-endemicity areas to interrupt transmission of the parasite.

The authors conclude, "a new tool for , RTS,S/AS01, is now available. Although its performance is somewhat disappointing in sub-Saharan African children, the vaccine's short-term efficacy could potentially be used in other regions and other age groups. Global efforts are currently underway to eliminate malaria, with a special focus in Southeast Asian areas with low malaria incidence and high antimalarial drug resistance. Integration of RTS,S/AS01 into elimination strategies may improve the chances of success."

More information: Roly Gosling et al. The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan, PLOS Medicine (2016). DOI: 10.1371/journal.pmed.1001994

Journal information: PLoS Medicine
Citation: Potential role for vaccine in malaria elimination (2016, April 12) retrieved 19 March 2024 from https://medicalxpress.com/news/2016-04-potential-role-vaccine-malaria.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Final trial results of the world's most advanced malaria vaccine announced

0 shares

Feedback to editors